Biocon Group News Today

Eli Lilly's CEO, David Ricks, outlines plans to launch the obesity drug Tirzepatide in India next year, presenting opportunities amid competition from Novo Nordisk. Bristol Myers Squibb expands its R&D footprint, eyeing India as a pivotal hub for innovation and clinical trials.

The $100-million facility, inaugurated by Boerner on Monday, is expected to employ over 1,500 employees and will be used to enhance its drug development through the use of digital technologies and artificial intelligence, he said in his keynote speech at the BioAsia conference.

Bristol Myers Squibb aims to expand its research and development presence in India and expects its newly inaugurated Hyderabad facility to become its largest unit outside the U.S. by 2025,...

Sen was appointed as the CFO of the company in April 2021 after Anupam Jindal stepped down. He has over 20 years of experience in financial planning, treasury, taxation and financial reporting.

These advancements reinforce the companys commitment to providing IT and security leaders with breach-ready confidence by stopping the lateral spread of malware.

Biocon has once again solidified its standing as a premier employer by retaining its position amongst the Top 10 Employers in the global biotech, pharma and biopharma sector, at No. 8 in 2023. This coveted recognition bestowed by the prestigious U.S.-based Science magazine underscores Biocon’s key quality attributes such as an ‘innovative leader in the

Kiran Mazumdar’s journey from a garage laboratory to leading a globally renowned biotech firm is an inspiration to aspiring entrepreneurs.

Kedar Upadhye has been appointed as the new Chief Financial Officer (CFO) of Biocon Biologics while current CFO, M.B. Chinappa will take on a strategic finance role at Biocon Group. These leadership changes will be effective October 31, stated ...

Biocon announced that its Board of Directors has approved the appointment of Peter Bains as Group CEO,...

Upadhye will be replace current CFO MB Chinappa who will take up strategic finance role at Biocon Group and will work with Peter Bains, the recently appointed Group CEO of Biocon. The leadership changes will be effective October 31, 2023, Biocon Biologics said in a statement.